Amerikanische Gesellschaft für Hirudotherapie

C-terminal peptide alcohol, acid and amide analogs of desulfato hirudin54-65 as antithrombin agents

Research article published in Thrombosis research (1989)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportArzneimittelentwicklungKrstenansky JL et al. · Thrombosis research, 1989

Abstract

Analogs of the antithrombin peptide hirudin54-65 with C-terminal modifications have been synthesized in order to examine the requirements for alpha-thrombin inhibition. The C-terminal residue, Gln65, could be replaced with L-amino acids or amino alcohols with neutral or charged hydrophilic side chains without greatly affecting the peptide's antithrombin potency as determined by inhibition of thrombin-induced clot formation in human plasma in vitro. Derivatives with D- or L-amino carboxamides at position 65 had significantly reduced potency, but still retained activity. Deletion of residue 65 with conversion of residue 64 to the amide or alcohol derivative resulted in a three-fold loss of potency. In addition to these results the solid-phase synthesis of peptide alcohols via direct displacement of p-nitrobenzhydrylideneisonitroso resin attached peptides with the desired C-terminal amino alcohol is reported.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAcidsAlcoholsAmidesAntithrombinsFemaleFibrinHirudinsHumansIn Vitro TechniquesPeptides

Zusammenfassung

Analogs of the antithrombin peptide hirudin54-65 with C-terminal modifications have been synthesized in order to examine the requirements for alpha-thrombin inhibition.

Warum dies für die Hirudotherapie relevant ist

This study synthesized C-terminal analogs of the antithrombin peptide hirudin54-65 with modifications at position 65 to examine the structural requirements for alpha-thrombin inhibition, measuring potency by inhibition of thrombin-induced clot formation in human plasma in vitro. Replacement of the C-terminal residue with L-amino acids or amino alcohols having neutral or charged hydrophilic side chains did not greatly affect antithrombin potency, whereas derivatives with D- or L-amino carboxamides at position 65 showed significantly reduced but retained activity; deletion of residue 65 produced a three-fold loss of potency. Because the abstract explicitly names hirudin54-65 as the parent peptide, the work has a defensible biochemical relevance to ASH's domain as a structure-activity study of a hirudin fragment. However, the abstract makes no mention of leeches, leech saliva, leech secretome, or hirudotherapy, and the study is purely in vitro.

Zitation

C-terminal peptide alcohol, acid and amide analogs of desulfato hirudin54-65 as antithrombin agents

Krstenansky JL et al. · Thrombosis research, 1989

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.